Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

SynAct Pharma (STO: SYNACT)

Last close As at 05/08/2026

SEK19.46

▲ 0.36 (1.88%)

Market capitalisation

SEK1,038m

SynAct Pharma is a clinical-stage biotechnology company focused on the development of treatments to resolve, rather than inhibit, ongoing inflammatory processes in acute and chronic diseases.

Latest News

Latest Insights

View More

Healthcare | Flash

SynAct Pharma — New financing enhances strategic flexibility

Healthcare | Comment

SynAct Pharma (STO: SYNACT) – preclinical resomelagon data support use in osteoarthritis

Healthcare | edison tv

SynAct Pharma – executive interview

Healthcare | Update

SynAct Pharma — Secondary endpoints reshape the debate

Market Data

Share Price SEK19.46
Market Cap SEK1,038m
52-Week High SEK25.30
52-Week Low SEK7.05
% Change 1M 1.2
% Change 6M (9.5)
% Change 12M (2.2)
Ave. Daily Volume 1yr 238,381
Visit Website

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Jeppe Øvlesen

    CEO

  • Ann Kristin Led

    CFO

Share Price Chart

Update

Healthcare

SynAct Pharma — Approaching a catalyst-rich period

Initiation

Healthcare

SynAct Pharma — Differentiated inflammation resolution approach

podcast

Healthcare

Bull, Bear & Beyond – SynAct Pharma: executive interview

edison tv

Healthcare

SynAct Pharma – executive interview